Abstract

Abstract Anaphylaxis is a severe life-threatening allergic reaction that is caused by mast cell hyperactivity. Two different mast cell receptors play critical roles in mediating anaphylaxis: 1) the IgE receptor that is stimulated by IgE-bound allergen and 2) the MRGPRX2 receptor that can bind to several cationic molecules and FDA-approved drugs resulting in mast cell activation. Activated mast cells degranulate to release proinflammatory mediators. We have recently identified that Na+/H+ exchanger regulatory factor 1 (NHERF1) regulates IgE-dependent mast cell activation in vitro and promotes passive cutaneous anaphylaxis (PCA) and passive systemic anaphylaxis (PSA) in vivo. In the current study, we investigated the role of this adapter molecule in affecting IgE-independent mast cell activation via the MrgprB2 (mouse orthologue of human MRGPRX2) receptor using a novel mouse strain, Cpa3-Cre+ NHERF1fl/fl that lacks NHERF1 in mast cells. PCA and PSA to compound 48/80 (a known MrgprB2 agonist) were significantly attenuated in the Cpa3-Cre+ NHERF1fl/fl mice as compared to control Cpa3-Cre− NHERF1fl/fl mice. In agreement with our in vivo data, peritoneal mast cells isolated from Cpa3-Cre+ NHERF1fl/fl mice showed a significant reduction in mast cell degranulation to the MrgprB2 ligands, compound 48/80 and substance P. Additionally, NHERF1-silenced human LAD2 mast cells showed decreased degranulation to these ligands as well. Collectively, our data suggests that NHERF1 promotes mast cell activation though the MRGPRX2/MrgprB2 receptor and determining the mechanisms through which NHERF1 modulates MRGPRX2 responses will lend insights into the development of new therapeutics for anaphylaxis and other allergic diseases.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call